Efficacy of combined local mechanical vibrations, continuous passive motion and thermotherapy in the management of osteoarthritis of the knee  by Kitay, G.S. et al.
Osteoarthritis and Cartilage (2009) 17, 1269e1274
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2009.04.015
International
Cartilage
Repair
SocietyEfﬁcacy of combined local mechanical vibrations, continuous passive
motion and thermotherapy in the management of osteoarthritis of the knee
G. S. Kitayy, M. J. Korenz*, D. L. Helfetx, M. K. Paridesk and J. A. Markenson{
y Jacksonville Orthopedic Institute, Jacksonville, FL, United States
z Jacksonville Center for Clinical Research, Jacksonville, FL, United States
xDepartment of Orthopaedic Surgery, Hospital for Special Surgery, New York, NY, United States
kDepartment of Health Policy, Mount Sinai School of Medicine Medical School, New York, NY, United States
{ Joan and Sanford Weill Medical College of Cornell University, New York, NY, USA
Summary
Objectives: We evaluated the efﬁcacy of combined mechanical vibrations, continuous passive motion (CPM) and heat on the severity of pain
in management of osteoarthritis of the knee (OA-K).
Methods: In this controlled, double crossover study, 71 OA-K patients were randomized in Phase 1 to receive 4 weeks active treatment con-
sisting of two 20-min sessions per day (34 patients, Group AB) or treatment with a sham device (37 patients, Group BA). This was followed by
a 2-week washout period (Phase 2). In Phase 3, patients crossed over so that Group AB was treated with the sham device and Group BA
received active treatment for an additional 4 weeks. Patient assessments of pain (visual analog scale, VAS) and Western Ontario and McMas-
ter Universities (WOMAC) OA index were performed at baseline and at study weeks 2, 4, 6, and 10. Net treatment effects were estimated by
comparing outcomes between active and sham treatment study phases.
Results: Treatment beneﬁts were noted for both of the trial’s two pre-speciﬁed primary endpoints, VAS and WOMAC. VAS was reduced at all
follow-up time points for patients receiving active treatment compared to sham treatment with a net treatment effect of 14.4 4.1 mm
(P¼ 0.001). Similarly, the WOMAC score was reduced signiﬁcantly with active treatment at all measured points with a net effect of
8.8 1.9 points (P< 0.001). The secondary endpoints, range of motion (ROM) and treatment satisfaction, also improved with active vs
sham treatment.
Conclusion: Four weeks treatment with combined CPM, vibration and local heating signiﬁcantly decreases pain, improves ROM and the
quality of life in patients with OA-K (ClinicalTrials.gov registration number: NCT00858416).
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Osteoarthritis, Heat therapy, Vibration therapy, Continuous passive motion.Introduction
Osteoarthritis (OA) is the most common form of joint dis-
ease worldwide, affecting 21 million adults in the United
States alone. In addition to pain, OA poses serious health
problems due to immobility, side effects of medications
and joint-related surgery complications. Currently accepted
treatment options for OA include patient education, weight
loss, physical rehabilitation, exercise1,2, modiﬁcation of ac-
tivities of daily living, food supplements and pharmacother-
apy. Non-steroidal anti-inﬂammatory drugs (NSAIDs) are
the most widely used pharmacologic treatment, but provide
incomplete effectiveness and can cause serious side
effects3e5. Non-pharmacologic measures such as weight
loss and adjusting physical activity are recommended by
all therapeutic guidelines and are aggressively promoted*Address correspondence and reprint request to: M. J. Koren,
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Boulevard South, Jacksonville, FL 32216, United States. Tel: 1-
904-730-0101; Fax: 1-904-730-0121; E-mail: MKoren@
encoredocs.com
Received 6 February 2008; revision accepted 19 April 2009.
1269by public health institutions. Unfortunately, compliance, es-
pecially over long periods of time, limits the effectiveness of
these modalities6. Since there is no accepted structure (dis-
ease) modifying therapy, the primary goals of contemporary
therapy are to reduce pain, improve joint function and im-
prove quality of life.
The role of various non-pharmacological therapies has
been investigated in the treatment of pain and as compo-
nents of physical rehabilitation in different orthopedic condi-
tions, though not all of the available approaches have been
speciﬁcally tested for treatment of osteoarthritis of the knee
(OA-K)7. For example, continuous passive motion (CPM)
has been investigated extensively in the setting of recovery
from total knee arthroplasty8e10 but not speciﬁcally for OA,
although there have been some studies testing active and
passive joint movement and muscle contraction7. Vibration
therapy has been tested for treatment of various types of
pain11,12 but not for OA7. Local heat has been investigated
for pain13,14 and anecdotal reports have appeared for OA15.
We hypothesized that combining these three modalities to-
gether would provide a signiﬁcant degree of symptomatic
relief with improved mobility. We elected to test a new de-
vice (Kineticure, Israel) that combines these three treatment
modalities.
1270 G. S. Kitay et al.: Efﬁcacy of combined local mechanical vibrations, CPM and thermotherapyMethodsPATIENTSThe study was a prospective, randomized, controlled, double crossover
study involving a total of 71 patients enrolled from an outpatient orthopedic
clinic at a single institution (Jacksonville Orthopedic Institute, Jacksonville,
FL). The study was approved by the Schulman Associates IRB, Inc. acting
on the authorization of the Baptist Medical Center, Jacksonville, FL with
which the clinic is afﬁliated (IRB #06-1297-0, approved on March 29,
2006) and the study was conducted in compliance with the Helsinki Declara-
tion. Patients were recruited between April 2006 and March 2007. Each pa-
tient provided informed consent prior to participation.
Consecutive patients were eligible for inclusion into the study if they were
between 45 and 80 years of age, had a diagnosis of OA-K by American Col-
lege of Rheumatology (ACR) criteria (with at least one osteophyte on X-
ray)16, had symptoms consistent with radiographic OA grades 2, 3 or 4 by
Kellgren and Lawrence criteria, and had moderate to severe knee pain
(35 mm on a 100 mm visual analog pain scale (VAS)). Patients were
also required to be ambulatory without assistance, be willing and able to par-
ticipate in the treatment protocol and follow-up visits and be able and willing
to provide informed consent. Patients were excluded from participation if they
had knee or hip surgery (including joint replacement) in the limb to be treated
at any time, if they had intra-articular visco-supplementation injections within
6 months, intra-articular corticosteroid injections within 2 months, signs or
symptoms suggestive of a non-OA cause of knee pain or a painful ankle
or hip in the same limb. Patients were also excluded if they had other dis-
eases that could result in pain or physical limitation in the treated limb,
change in pain medications (type, frequency and dosage), physiotherapy,
acupuncture, natural remedies or use of orthotic devices within 2 weeks.
Following enrollment, patients were randomized into one of two groups:
Group AB or Group BA. Randomizations were in blocks of 4. Randomization
codes were concealed in sequentially numbered envelopes prepared by the
sponsor that were stored at the site and opened by the study coordinator fol-
lowing each patient enrollment. The study was divided into three periods as
summarized in Fig. 1. Phase 1 was a 4-week period in which Group AB pa-
tients received active treatment with the Kineticure device while Group BA
patients were treated with a sham device (both devices described below).
Phase 1 was followed by a 2-week ‘‘washout period (WO)’’ during which
no treatments were administered (Phase 2). Study Phase 3 was a 4-weekPHASE 3
Group BA (37)
Informed Consent
Screening
Randomization
(71)
4 Weeks
Sham Treatment
2 Weeks
Washout
4 Weeks
Active Treatment
Group AB (34)
2 Weeks
Washout
4 w/d
4 Weeks
Sham Treatment
(n=24)
4 Weeks
Active Treatment
(n=32)
PHASE 1
PHASE 2
8 w/d
5 w/d 2 w/d
19 Completers 30 Completers 
1 w/d2 w/d
Fig. 1. Overview of this prospective, double crossover study. Num-
bers in parentheses show number of patients entering the various
phases of the study. w/d, withdrawn from study (refer to Table II
for reasons for w/d).period in which Group BA patients received active treatment with the Kinet-
icure device while Group AB patients were treated with the sham device.
Thus, the duration of each subject’s participation was 10 weeks. Patients
were instructed not to alter other treatments (e.g., types and amounts of
non-steroidal medications) that were present during the 2 weeks prior to en-
rollment and throughout the study duration; in cases where changes oc-
curred that could have inﬂuenced outcomes, patients were withdrawn from
the study (as detailed below).ACTIVE AND SHAM TREATMENTSAlthough the study was not blinded to investigators, efforts were made to
minimize bias with the use of a sham device. The active and sham devices
looked identical. Patients were speciﬁcally not informed of the exact nature of
the active treatment (other than it involved wearing a knee brace) or the dif-
ferences between the active and sham devices.
Active treatment was provided by the Kineticure system 20 min per ses-
sion, twice per day for 4 weeks. The system consists of a knee brace with
integrated heating pad and vibration unit, and a foot pedal that delivers
CPM (Fig. 2). The knee brace is composed of a stretchable textile support
that is placed around the knee and a polyurethane case that houses the vi-
bration motor, the batteries and a printed circuit board (that controls the vi-
bration unit); a hinge in this casing allows for movement of the knee during
CPM. The brace is held in place with an adjustable buckle strap above the
knee and an adhesive strap below the knee that are integrated into the textile
support, with the polyurethane case on the lateral side of the knee. The fre-
quency of vibration is varied repeatedly over four 10-second periods: 10 s at
10 Hz, 10 s at 27 Hz, 10 s at 42 Hz and 10 s of no vibrations. Each treatment
period, which lasts 20 m, therefore consists of 30 such cycles. As seen in
Fig. 2, vibrations are transmitted to the leg just above and just below the
knee through the polyurethane casing (which span a quarter to a third of
the leg circumference in each location) and through the straps that extend
around the entire leg at both locations. Heating is provided by a commercially
available exothermic heating pad that is inserted into a pocket on the inner
side of the textile support prior to each treatment. This heating pad attains
temperatures of 40.0e40.5C within 30 min of being activated by simply
opening the package; patients are asked, therefore, instructed to active
the pad 30 min prior to starting the treatment period. The temperature is
maintained for the 2 h treatment periods. The foot pedal cycles through
45 every 10 s.
As already noted, the sham device looked the same as the active device,
but consisted of a non-vibrating knee brace with no heating pads or foot
pedal. As for periods of active treatment, patients were instructed to wear
their knee brace twice a day for 20 min during the designated 4-week
sham study periods.OUTCOME MEASURESThe primary outcome measures of this study were intensity of pain as
measured on a 100 mm non-marked VAS and the total Western Ontario
and McMaster Universities (WOMAC) OA index using a Likert scale, withFoot Pedal
Adhesive Strap
Buckle Strap
On/OFF Button
Hinge
Fig. 2. Picture of the device will all its components as labeled.
1271Osteoarthritis and Cartilage Vol. 17, No. 10scores ranging from 0 (no pain, no disability) to 96 (maximal disability and
pain) points17.
Secondary outcome measures of this study were VAS of satisfaction of
use of the Kineticure device as measured on a 0e100 mm non-marked scale
and range of motion (ROM) of the knee (using goniometer) and knee circum-
ference, both measured by a trained investigator blinded to treatment group.
All parameters were measured prior to initiation of treatment, after provid-
ing the ﬁrst treatment in the clinic to assess the immediate effect, and during
follow-up visits to the clinic every 2 weeks. Treatments were not applied in
the clinic on the days of the follow-up visits.SAMPLE SIZESample size was determined to ensure 90% power to detect a difference
between active and sham treatments for each of the two co-primary end-
points of at least 0.9 standard deviation (SD) units based on two-tailed
0.025 level t-test. Based on these criteria, a total of 60 patients (30 in
each group) are required. The trial randomized 11 additional patients (for a to-
tal of 71) in anticipation of a 15% drop out rate.STATISTICAL ANALYSISData from this crossover study were analyzed using a mixed model anal-
ysis of variance as described in Brown and Prescott18. Estimates of the treat-
ment effect for each period were based on the difference between the
baseline measurement and the end of period treatment measurement at
10 weeks post baseline. The signiﬁcance of the treatment effect was based
on a t-test, with degrees of freedom determined using Saterthwaite’s approx-
imation. Given that two co-primary endpoints were pre-speciﬁed, each test
was conservatively conducted at a two-sided 0.025 level, in order to maintain
an overall Type I error probability of 0.025. All analyses were conducted us-
ing PROC MIXED, version 9.1, SAS Institute Inc., Cary, NC.Results
A total of 71 patients signed informed consent, passed
baseline screening and were randomized between Group
AB (n¼ 34) and Group BA (n¼ 37). The baseline charac-
teristics of the patients for the two groups are summarized
in Table I and show that randomization resulted in groups
with similar characteristics (Table I). The overall ﬂow of pa-
tients through the study is summarized in Fig. 1. A total of
22 patients dropped out at some point before the end of
the study. Fifteen patients in Group AB dropped out during
the study leaving 19 completed as compared to seven drop
out patients in Group BA and 30 completed subjects. We
could not identify a reason for the overall imbalance in drop-
outs between groups, resulting in a greater number ofTable I
Baseline demographics and entry pain and stiffness scores
Group AB sham
treatment followed
by active treatment
(meanSD)
Group BA active
treatment followed
by sham treatment
(meanSD)
Age (years) 64.1 9.5 58.7 8.2
Height (cm) 165.7 10.1 169.5 13.4
Weight (kg) 92.6 19.4 99.6 23.2
BMI 33.7 6.6 34.7 7.3
Men (%) 44.0% 48.6%
VAS for pain (mm) 70.4 18.6 65.1 17.4
WOMAC score
Total 46.1 14.2 44.1 14.1
Pain 9.6 2.9 10.5 3.3
Stiffness 4.2 1.4 4.6 1.4
Physical function 32.2 11.0 29.1 1.8
ROM (() 108 21 106 24
WOMAC, Western Ontario and McMaster Universities Likert
scale. BMI, body mass index.Group BA completes. Baseline demographic characteristics
of patients who dropped out were similar to those of patients
who remained in the study. Reasons for drop out by study
group and study period are summarized in Table II. Eight
patients were either unable or unwilling to comply with the
schedule of study visits. Five patients had signiﬁcant
changes in pain medications and were dropped at the dis-
cretion of the Principal Investigator. Three patients dropped
out during active treatment because they felt they were not
deriving beneﬁt, compared to one drop out for this reason
during a period of sham treatment.
Overall, the device was well tolerated and easily used by
most patients. There were no serious adverse events. The
time courses of change of the primary and secondary end-
points are summarized in Figs. 2e5. Pain, quantiﬁed by the
visual analog scale (VAS), signiﬁcantly improved with ac-
tive treatment compared with sham during both treatment
periods. The net difference in change of VAS between ac-
tive and sham treatments (calculated as detailed above)
averaged 14.4 4.1 VAS points (P¼ 0.001). Of note, ac-
tive treatment resulted in signiﬁcantly improved VAS during
Phases III despite the fact that the Phases III active
treatment group started with higher VAS. WOMAC im-
proved signiﬁcantly between active and sham treatment
in both Phases 1 and 3 (average 8.8 1.9 points,
P< 0.001). Again, Phase 3 beneﬁts were apparent despite
an initial imbalance in WOMAC scores at the time of cross-
over between treatments. The pain stiffness and physical
function dimensions of WOMAC each improved signiﬁ-
cantly with active treatment compared to sham treatment
by 2.2, 1.1 and 6.0 points respectively (P< 0.001 for
each parameter).
During study Phase 1, ROM showed no improvement
with sham treatment, but improved signiﬁcantly with active
treatment. This improvement waned minimally during the
WO and during the initial half of study Phase 3. For sham
patients however, at the end of Phase 3, there were no dif-
ferences between groups. Overall, the net treatment effect
on ROM was 4.6 1.9 (P¼ 0.02) during the entire study
course.
Finally, there was a high degree of patient treatment sat-
isfaction as judged immediately after the ﬁrst treatment
(Fig. 6). This occurred for both the sham (placebo effect)
and active treatments. However, the degree of satisfaction
was signiﬁcantly great with the active treatment. Over
time, satisfaction was maintained with active treatment,
but waned with sham treatment. These same patterns
emerged after crossover. The net treatment effect on satis-
faction averaged 51 points (P¼ 0.002).Table II
Reasons for discontinuation by group and study period
Group AB Group BA
ActiveþWO Sham Active ShamþWO
Went to surgery 1
Not deriving beneﬁt 2 1 1
Device uncomfortable 1
Device inconvenient 1
Too difﬁcult to
operate device
1
Change of medications 2 1 2
Unable or unwilling to
return to clinic
4 2 2
Unrelated intercurrent
injury
1
Phase 1 Phase 2 Phase 3
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Fig. 3. Changes in visual analog scale (VAS) of pain (in units of mil-
limeters) as a function of group and phase of study. See text for
details.
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Fig. 5. Changes in ROM as a function of group and phase of study.
See text for details.
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In a prospective, controlled, double crossover study, pa-
tients with OA-K were treated in 4-week cycles with a sys-
tem that combines vibration, local heat and passive
motion. When compared to a sham treatment, active
treatment signiﬁcantly reduced pain, reduced stiffness and
improved physical function as measured by VAS and
WOMAC subscale scores. Secondary measures also im-
proved as measured by ROM and degree of treatment sat-
isfaction. No adverse effects were reported during the
4-week treatment period.
Concern over side effects of NSAIDs has led patients to
seek, and investigators to develop, alternative treatments.
For example, two prior reports showed that moderate exer-
cise may improve joint symptoms and function OA-K19,20. A
different approach tested the effectiveness of acupuncture
over 26 weeks. That study showed signiﬁcantly improvedPhase 1 Phase 2 Phase 3
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Fig. 4. Changes in WOMAC OA index using a Likert scale. See text
for details.pain score (40% decrease from baseline)21. Our results
show decrease in pain in a similar range (39% from base-
line). Yet another category of treatment for OA are braces
and neoprene sleeve knee supports. In clinical trials,
when compared to medical treatment, it has been shown
that these devices have limited additional beneﬁcial effect
for pain and function in OA-K22.
Prior studies have examined CPM8e10, vibration11,12 and
heat13,14 separately for treatment of pain in various orthope-
dic conditions, though not speciﬁcally in OA-K7,15. CPM is
indicated in post-total knee replacement therapy, with
proven beneﬁts in improving mobility, ROM and functional-
ity. Limitations of CPM are inconvenience and substantial
costs. Vibration therapy is known to have many different
physiologic and therapeutic effects depending on its accel-
eration, amplitude, frequency, length of exposure and
method of application. In addition to reduced pain inPhase 1 Phase 2 Phase 3
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1273Osteoarthritis and Cartilage Vol. 17, No. 10a variety of settings11,23e25, increased circulation (blood,
lymph, other bodily ﬂuids) has also been demonstrated16,26.
In addition, microvascular ﬁltration is shifted with vibration,
producing a pronounced increase in the threshold for
edema formation because lymphatic ﬂow is increased24. Vi-
bration also activates cell surface motion-receptors and in-
ﬂuences cellular functions such as growth-rate and
substance production such as proteoglycan27,28. Vibration
treatment also improves muscle force through mechanisms
such as the tonic vibration reﬂex, improved nerve-muscle
function, realignment of muscle ﬁbers and increased sub-
stance production by secretory cells29e33. Vibration has
also been shown to be helpful in some aspects of pain man-
agement11,12,34. On the other hand, it is known from studies
of both experimental animals35 and humans36 that vibration
can stimulate bone formation. If, in the long term, this stim-
ulates osteophyte growth or leads to stiffening of the sub-
chondral cansellous bone, there could be negative
consequences on pain and overall outcome37.
Two forms of heat therapy are available. Superﬁcially ap-
plied treatments, such as hot packs, heat the skin and sub-
cutaneous tissues, while deep heating agents such as
therapeutic ultrasound (US) may produce temperature ele-
vations of 4e5C at depths of 8 cm38. However, in a sys-
temic review of the literature, treatment with hot packs did
not demonstrate any signiﬁcant beneﬁcial effect when
used to treat OA38.
Although the present study was under powered to deﬁni-
tively prove safety, no adverse events or ill effects were re-
ported in this study. It is interesting to note that regulatory
bodies such as Occupational Safety and Health Administra-
tion (OSHA) and the International Organization for Standard-
ization (ISO) discuss potential health issues arising from
chronic exposure to vibration. Although they do not speciﬁ-
cally comment on standards for vibration exposure to the
knee, they do provide guidance for hand and wrist, as well
as whole body exposure. These standards provide limits
and boundaries for vibration exposures over an 8 h per day
and provide values of 5 m/s2 for the hand and 9 m/s2 for the
entire body. Assuming an amplitude of vibration provided
by the Kineticure device on the order of 0.1 mm (which we
take as an over estimate), the acceleration provided at the
maximum frequency would be approximately 7 m/s2. Given
that this value is less than the boundary set for the whole
body exposure and that the duration of vibration application
is less than 40 min per day (i.e., two 20-min sessions, with
1⁄4 of the time without vibrations), this level of exposure,
basedon these standards, ismarkedly less thanwould be ex-
pected to cause any untoward effects, even during chronic
daily use over long periods of time.
Limitation of the present study include the limited number
of participants, the relatively short treatment period and the
unblinded nature of the study. Hence, it would be important
to study a longer treatment period to examine durability of re-
sponse. Although efforts were made to minimize placebo ef-
fect (e.g., use of a shamdevice,minimal information provided
to patients about the nature of the treatment and use of inves-
tigators blinded to treatment group to conduct evaluations), it
is recognized that patients could not be blinded to the nature
of the treatment. Accordingly, the true impact on pain andmo-
tion could be less than the current results indicate. This would
even include ROM measurements which, in the absence of
a validation of measurement reproducibility and objectivity,
could have been inﬂuenced by investigator bias. It would
also be interesting to consider the residual effect (i.e., how
long the beneﬁt last after the therapy discontinued) achieved
with this device. It would be interesting to investigatedurability of the effect in light of ﬁndings noted above in exper-
imental animals and humans that vibration may bone forma-
tion which could have negative consequences in the setting
ofOA.As seen inFigs. 2e5, outcomemeasuresdidnot return
to baseline by the end of the WO following the ﬁrst treatment
period. Suggesting the duration of residual effect of a 4weeks
treatment course is more than 2 weeks. Another limitation of
the study was the relatively high drop out rate; the drop out
was largely because patient noncompliance with the study
visit schedule and because of changes in pain medications
which would have interfered with interpretation of the ﬁnd-
ings. Finally, we measured the impact of simultaneous
heat, vibration and passive motion treatment; therefore we
cannot determine the relative contributions of each of the
three components to the overall treatment effects.
The strengths of the present study are that this is the ﬁrst
time that combined treatment with CPM, vibration and local
heating for OA-K has been investigated and shown to have
a beneﬁcial effect on pain and quality of life, along with
ROM improvement following 4 weeks of treatment. The
crossover study design, considered to be the best for eval-
uating treatment modalities in OA, also allowed for collec-
tion of efﬁcacy data in a larger number of patients.Conclusions
In this double crossover study, 4 weeks of treatment with
combined CPM, vibration and local heating signiﬁcantly im-
proved pain, quality of life and ROM in patients with OA-K.
In addition, the treatment appears to be safe (at least during
4-week treatment period) and, along with its demonstrated
efﬁcacy, provides an attractive primary or adjunctive treat-
ment for this condition39.Conﬂict of interest
This study was supported by Kineticure, Inc. Helfet DL
and Markenson JA are paid consultants to Kineticure.References
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